ATRX and central nervous system cancer: Moreover, the mutation rates of common mutant genes in glioma in the high-risk group were significantly higher than those in the low-risk group, such as IDH1 (70% vs. 50%), TP53 (42% vs. 36%), ATRX (33% vs. 25%) and EGFR (8% vs. 5%) (Fig. S8A-B).